{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T14:50:00Z","timestamp":1781967000647,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hengyang Central Hospital Doctoral Research Start-up Fund","award":["HYZXYY2023091205"],"award-info":[{"award-number":["HYZXYY2023091205"]}]},{"name":"The Science and Technology Program of Hunan Province","award":["2025JJ80595"],"award-info":[{"award-number":["2025JJ80595"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04425-2","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:50:24Z","timestamp":1781963424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of cancer-associated fibroblast subtypes in the prostate cancer microenvironment and their clinical implications: prognostic model construction and therapeutic target exploration based on bioinformatics analysis"],"prefix":"10.1007","author":[{"given":"Zifang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5649-7384","authenticated-orcid":false,"given":"Zhijun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"1","key":"4425_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4425_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84(2):191\u2013206.","journal-title":"Eur Urol"},{"issue":"2","key":"4425_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"key":"4425_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ (Clin Res ed). 2018;362:k3519.","journal-title":"BMJ (Clin Res ed.)"},{"key":"4425_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"4425_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"4425_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"3","key":"4425_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41(3):434\u201349.","journal-title":"Cancer Cell"},{"key":"4425_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.05.016","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell. 2023. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.016.","journal-title":"Cancer Cell"},{"issue":"14","key":"4425_CR10","doi-asserted-by":"publisher","first-page":"e175949","DOI":"10.1172\/JCI175949","volume":"134","author":"B Zhang","year":"2024","unstructured":"Zhang B, et al. Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts. J Clin Investig. 2024;134(14):e175949.","journal-title":"J Clin Investig"},{"issue":"6","key":"4425_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41568-023-00587-1","volume":"23","author":"G Brewer","year":"2023","unstructured":"Brewer G. CAFs promote CRPC. Nat Rev Cancer. 2023;23(6):349.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4425_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","volume":"38","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell. 2020;38(2):279\u201396.","journal-title":"Cancer Cell"},{"issue":"12","key":"4425_CR13","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"6","key":"4425_CR14","doi-asserted-by":"publisher","first-page":"F826","DOI":"10.1152\/ajprenal.00284.2023","volume":"325","author":"G Apodaca","year":"2023","unstructured":"Apodaca G. Defining the molecular fingerprint of bladder and kidney fibroblasts. Am J Physiol Renal Physiol. 2023;325(6):F826\u201356.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"4425_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/cas.15609","volume":"114","author":"Y Yamamoto","year":"2023","unstructured":"Yamamoto Y, et al. The heterogeneity of cancer-associated fibroblast subpopulations: their origins, biomarkers, and roles in the tumor microenvironment. Cancer Sci. 2023;114(1):16\u201324.","journal-title":"Cancer Sci"},{"key":"4425_CR16","doi-asserted-by":"publisher","first-page":"1133160","DOI":"10.3389\/fimmu.2023.1133160","volume":"14","author":"J Pan","year":"2023","unstructured":"Pan J, et al. Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front Immunol. 2023;14:1133160.","journal-title":"Front Immunol"},{"issue":"9","key":"4425_CR17","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","volume":"27","author":"PM Galbo","year":"2021","unstructured":"Galbo PM, Zang X, Zheng D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27(9):2636\u201347.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4425_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12967-023-04807-y","volume":"22","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer. J Transl Med. 2024;22(1):57.","journal-title":"J Transl Med"},{"issue":"5","key":"4425_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109674","volume":"27","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, et al. Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. iScience. 2024;27(5):109674.","journal-title":"iScience"},{"issue":"22","key":"4425_CR20","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/0008-5472.CAN-24-0932","volume":"84","author":"H Song","year":"2024","unstructured":"Song H, et al. YAP1 inhibition induces phenotype switching of cancer-associated fibroblasts to tumor suppressive in prostate cancer. Cancer Res. 2024;84(22):3728\u201342.","journal-title":"Cancer Res"},{"issue":"12","key":"4425_CR21","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ijc.34708","volume":"153","author":"PV Salachan","year":"2023","unstructured":"Salachan PV, et al. Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer. Int J Cancer. 2023;153(12):2055\u201367.","journal-title":"Int J Cancer"},{"issue":"1","key":"4425_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12967-024-05413-2","volume":"22","author":"M Talia","year":"2024","unstructured":"Talia M, et al. Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients. J Transl Med. 2024;22(1):597.","journal-title":"J Transl Med"},{"issue":"6","key":"4425_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41556-022-00918-8","volume":"24","author":"II Verginadis","year":"2022","unstructured":"Verginadis II, et al. A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat Cell Biol. 2022;24(6):940\u201353.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"4425_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/path.6207","volume":"262","author":"J Thorlacius-Ussing","year":"2024","unstructured":"Thorlacius-Ussing J, et al. The collagen landscape in cancer: profiling collagens in tumors and in circulation reveals novel markers of cancer-associated fibroblast subtypes. J Pathol. 2024;262(1):22\u201336.","journal-title":"J Pathol"},{"issue":"1","key":"4425_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09736-5","volume":"22","author":"C Ucaryilmaz Metin","year":"2022","unstructured":"Ucaryilmaz Metin C, Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. BMC Cancer. 2022;22(1):692.","journal-title":"BMC Cancer"},{"key":"4425_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415970","author":"H Chen","year":"2022","unstructured":"Chen H, et al. Integrated analysis revealed an inflammatory cancer-associated fibroblast-based subtypes with promising implications in predicting the prognosis and immunotherapeutic response of bladder cancer patients. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232415970.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"4425_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34876","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, et al. Characterization of the tumor microenvironment in breast cancer brain metastasis. Heliyon. 2024;10(15):e34876.","journal-title":"Heliyon"},{"issue":"19","key":"4425_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202416523","volume":"12","author":"W Li","year":"2025","unstructured":"Li W, et al. Halofuginone disrupted collagen deposition via mTOR-eIF2\u03b1-ATF4 axis to enhance chemosensitivity in ovarian cancer. Adv Sci (Weinh). 2025;12(19):e2416523.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"4425_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/1759-7714.12947","volume":"10","author":"S Fang","year":"2019","unstructured":"Fang S, et al. Clinical significance and biological role of cancer-derived type I collagen in lung and esophageal cancers. Thorac Cancer. 2019;10(2):277\u201388.","journal-title":"Thorac Cancer"},{"key":"4425_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2026.178601","volume":"1015","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, et al. Bufotalin targets COL1A1 to suppress non-small cell lung cancer growth and remodel the tumor microenvironment via dual inhibition of PI3K\/AKT\/mTOR and MAPK pathways. Eur J Pharmacol. 2026;1015:178601.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4425_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41419-025-07974-6","volume":"16","author":"Q Wang","year":"2025","unstructured":"Wang Q, et al. Targeting LINC01711 in FAP(+) cancer-associated fibroblasts overcomes lactate-mediated immunosuppression and enhances anti-PD-1 efficacy in lung adenocarcinoma. Cell Death Dis. 2025;16(1):642.","journal-title":"Cell Death Dis"},{"issue":"1","key":"4425_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112153","volume":"394","author":"M Li","year":"2020","unstructured":"Li M, et al. Microenvironment remodeled by tumor and stromal cells elevates fibroblast-derived COL1A1 and facilitates ovarian cancer metastasis. Exp Cell Res. 2020;394(1):112153.","journal-title":"Exp Cell Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04425-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04425-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04425-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:50:31Z","timestamp":1781963431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04425-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":32,"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04425-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses were based on previous published studies; thus, no ethical approval and patient consent are required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}